Researchers compare the effectiveness and acceptability of oral monotherapy with psychedelics for the treatment of depressive symptoms.
Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate – Pharmaceutical Technology
Johnson & Johnson’s nipocalimab (M-281) is under clinical development in Phase II for rheumatoid arthritis. Credit: one photo via Shutterstock. The patent for Janssen’s second-generation,